Autism Pervasive developmental disorders
Conditions
Interventions
In Arm 1, the subjects will receive 24IU/dose of intranasal oxytocin (Syntocinon Nasal Spray, NOVARTIS) administration twice daily for one month followed by one week washout period.Then they will rece
Sponsors
Osaka University Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: All participants will be recruited from the outpatients of Osaka Univercity hospital if they meet the inclusion criteria as follows;1) having clinical diagnosis for autism spectrum disorders as assessed by use of DSM-4-TR (Text Revision of the Diagnostic and Statistical Manual of Mental Disorders,4th edition),and 2) having IQ between 35-75.
Exclusion criteria
Exclusion criteria: We will exclude patients with cardio vascular disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The outcome measures are Abberant Behavior Checklist(ABC),Child Behavior Checklist(CBCL),Social Responsiveness Scale(SRS) completed by the caregivers and eye tracking tested before the administration of nasal oxytocin and at the end of each term(placebo or oxytocin). In addition,we will analyze mutations of CD38. | — |
Secondary
| Measure | Time frame |
|---|---|
| The second outocome measures are blood pressure,urine osmolarity,urine sodium concentration and oxytocin concentration of his second urine in the morning.They are measured every time the participant comes to the hospital during the trial. | — |
Countries
Japan
Contacts
Public ContactIkuko Hirata
Osaka University Graduate School of Medicine Department of Pediatrics
Outcome results
None listed